ArticleEuropean journal of nuclear medicine and molecular imaging2026
Radiation induced lymphopenia during PRRT: Incidence, course, predictive factors, and association with overall survival.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRadiation induced lymphopenia (RIL) is a predictive factor for overall survival in external beam radiotherapy (EBRT). Since both peptide receptor radionuclide therapy (PRRT) and EBRT utilize radiation for treatment effect, RIL could also be a factor in PRRT.
aimThe aim of this study was (1) to determine the incidence of radiation induced lymphopenia during PRRT (2) identify factors that predict lymphopenia during PRRT, and (3) determine the association of lymphopenia during PRRT on overall survival.
methodsAll patients undergoing PRRT between 2015 and 2023 were included in this retrospective study. PRRT consisted of four cycles of 7.4 GBq of [177Lu]Lu-HA-DOTATATE. Hematological assessment was performed at baseline and both three and six weeks after every cycle of PRRT. Uptake of [177Lu]Lu-HA-DOTATATE was measured on the post-therapy SPECT/CT after 24 h after the first cycle of therapy. Binary logistic regression was used to identify factor predicting lymphopenia and cox regression was used to determine the association between severe grade 3–4 lymphopenia and overall survival.
resultsA total of 211 patients were included in the study, of which 45.5% developed grade 1–2 lymphopenia and 45.4% developed grade 3–4 lymphopenia. Overall survival was 56 months [95%CI 39–73 months] for patients with grade 0–2 lymphopenia compared to 39 months [95%CI 33–45 months] in the group with grade 3–4 lymphopenia (p = 0.016). Grade 3–4 lymphopenia was a risk factor for worse overall survival compared to grade 0–2 lymphopenia (HR1.68, 95%CI 1.09–2.58, p = 0.018). The total number of cycles of PRRT and baseline lymphocytes counts were risk factors for the development of grade 3–4 lymphopenia (p < 0.001).
conclusionRadiation induced lymphopenia occurs in the majority of patients during PRRT, with 47% developing severe grade 3–4 lymphopenia. The development of severe RIL is associated with worse overall survival and can be partially predicted by baseline lymphocyte levels and the number of cycles of PRRT. Further research is needed in the relationship between lymphocyte radiation dose and lymphopenia and possible strategies to prevent severe lymphopenia from occurring.
Indexed as
Identifiers
41857356What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.